Kimberly Blackwell
Chief Executive Officer at ZENTALIS PHARMACEUTICALS, INC.
Net worth: 8 M $ as of 30/03/2024
Profile
Dr. Kimberly L.
Blackwell, MD, is an Independent Director at Century Therapeutics, Inc., a Chief Executive Officer & Director at Zentalis Pharmaceuticals, Inc., an Independent Director at Monte Rosa Therapeutics, Inc. and a President at Cereius, Inc. She is on the Board of Directors at Fore Biotherapeutics, Inc., Century Therapeutics, Inc., Zentalis Pharmaceuticals, Inc. and Monte Rosa Therapeutics, Inc. Dr. Blackwell was previously employed as an Independent Director by Century Therapeutics, Inc. /Old/, a Chief Medical Officer & SVP-Clinical Oncology by Tempus Labs, Inc., a VP-Early Phase Oncology & Immuno-Oncology by Eli Lilly & Co., a Director-Women's Cancer Program & Professor by Duke Cancer Institute, a Professor by Duke University, and a Vice President-Early Phase Oncology by Lilly Oncology.
She also served on the board at Neoantigenics, Inc. She received her undergraduate degree from Duke University and a doctorate degree from Mayo Clinic College of Medicine & Science.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 31/01/2024 | 484,145 ( 0.68% ) | 8 M $ | 30/03/2024 | |
| 13/06/2023 | 0 ( -.--% ) | - $ | 30/03/2024 | |
| 26/06/2023 | 0 ( -.--% ) | - $ | 30/03/2024 |
Kimberly Blackwell active positions
| Companies | Position | Start |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Chief Executive Officer | 09/05/2022 |
| MONTE ROSA THERAPEUTICS, INC. | Director/Board Member | 31/05/2020 |
| CENTURY THERAPEUTICS, INC. | Director/Board Member | 30/04/2021 |
Fore Biotherapeutics, Inc.
 Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Director/Board Member | 19/09/2021 |
Cereius, Inc.
 Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Founder | 31/12/2016 |
Former positions of Kimberly Blackwell
| Companies | Position | End |
|---|---|---|
Tempus Labs, Inc.
 Tempus Labs, Inc. Information Technology ServicesTechnology Services Tempus Labs, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL. | Chief Tech/Sci/R&D Officer | 15/05/2022 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 29/02/2020 |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | Corporate Officer/Principal | 31/12/2017 |
Duke Cancer Institute
 Duke Cancer Institute Hospital/Nursing ManagementHealth Services Duke Cancer Institute is an organization that unites the academic and clinical communities of Duke University and the Duke University Health System. The non-profit company is based in Durham, NC and has subsidiaries in the United States. The company's main focus is to provide access to technologies, services, and scientific consultation through its Shared Resources. | Corporate Officer/Principal | 31/12/2017 |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Kimberly Blackwell
| Duke University | Undergraduate Degree |
| Mayo Clinic College of Medicine & Science | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| CENTURY THERAPEUTICS, INC. | Health Technology |
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| MONTE ROSA THERAPEUTICS, INC. | Health Technology |
| Private companies | 7 |
|---|---|
Neoantigenics, Inc.
 Neoantigenics, Inc. Medical SpecialtiesHealth Technology Neoantigenics, Inc. developes therapeutic plus diagnostic products. The firm focuses on developing oncology theranostics products, founded on the novel science around oocyte (egg)-associated cancer proteins. The company was founded Brian A. Pollok, John C. Herr and Edward J. Leary in July 2012 and is headquartered in Charlottesville, VA. | Health Technology |
Lilly Oncology
 Lilly Oncology Hospital/Nursing ManagementHealth Services Part of Eli Lilly & Co., Lilly Oncology is an American company dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. With over 50 years of experience, Lilly Oncology is committed to building on their heritage and improving the lives of all those affected by cancer worldwide. | Health Services |
Fore Biotherapeutics, Inc.
Fore Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA. | Health Technology |
Tempus Labs, Inc.
Tempus Labs, Inc. Information Technology ServicesTechnology Services Tempus Labs, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL. | Technology Services |
Duke Cancer Institute
Duke Cancer Institute Hospital/Nursing ManagementHealth Services Duke Cancer Institute is an organization that unites the academic and clinical communities of Duke University and the Duke University Health System. The non-profit company is based in Durham, NC and has subsidiaries in the United States. The company's main focus is to provide access to technologies, services, and scientific consultation through its Shared Resources. | Health Services |
Cereius, Inc.
Cereius, Inc. BiotechnologyHealth Technology Cereius, Inc. develops novel radio-labeled therapeutics for treating solid tumor brain metastasis. The firm delivers new targeted classes of both radiologic diagnostics and radiotherapeutics for the treatment of cancers in the brain. The company was founded by Kimberly Blackwell and Michael R. Zalutsky in 2017 and is headquartered in Durham, NC. | Health Technology |
Century Therapeutics, Inc. /Old/
 Century Therapeutics, Inc. /Old/ BiotechnologyHealth Technology Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA. | Health Technology |
- Stock Market
- Insiders
- Kimberly Blackwell
